The introduction of biosimilar monoclonal antibodies (mAbs) into the market is thought to be eagerly awaited by payers. This is motivated by the need to constrain prescribing costs due to the ever burdening pressure on healthcare budgets. With a number of originator mAbs products approaching patent expiry, biosimilar mAbs will be a reality in the near future. Read conclusions of this Double Helix Consulting analysis here. (Source: ISPOR.org)
You are here: / The Introduction of mAbs into Developed Markets: What are payers concerned about?